These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 20951178)

  • 21. The farmyard drug store.
    Nature; 2006 Sep; 443(7107):16-7. PubMed ID: 16957702
    [No Abstract]   [Full Text] [Related]  

  • 22. Some monoclonal anti-human lymphocyte and class II MHC antigen antibodies do not stain snap frozen Macaca fascicularis lymphocytes or tissue sections.
    Li A; Forsum U
    J Med Primatol; 1991 Jul; 20(5):262-4. PubMed ID: 1717689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry.
    Stone JA; Banfield C; Pfister M; Tannenbaum S; Allerheiligen S; Wetherington JD; Krishna R; Grasela DM
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):20S-30S. PubMed ID: 20881214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surrogate approaches in development of monoclonal antibodies.
    Bornstein GG; Klakamp SL; Andrews L; Boyle WJ; Tabrizi M
    Drug Discov Today; 2009 Dec; 14(23-24):1159-65. PubMed ID: 19853060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives.
    Oh EJ; Park K; Kim KS; Kim J; Yang JA; Kong JH; Lee MY; Hoffman AS; Hahn SK
    J Control Release; 2010 Jan; 141(1):2-12. PubMed ID: 19758573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chinese biotech hamstrung by production issues.
    Jia H
    Nat Biotechnol; 2007 Feb; 25(2):147-8. PubMed ID: 17287733
    [No Abstract]   [Full Text] [Related]  

  • 27. Considerations in assessing the developmental and reproductive toxicity potential of biopharmaceuticals.
    Martin PL; Breslin W; Rocca M; Wright D; Cavagnaro J
    Birth Defects Res B Dev Reprod Toxicol; 2009 Jun; 86(3):176-203. PubMed ID: 19462404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
    Fleuranceau-Morel P
    Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
    Smart A; Martin P
    Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuous bioprocessing: the real thing this time? 10(th) Annual bioProcessUK Conference, December 3-4, 2013, London, UK.
    Farid SS; Thompson B; Davidson A
    MAbs; 2014; 6(6):1357-61. PubMed ID: 25484060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor.
    Skartved NJ; Jacobsen HJ; Pedersen MW; Jensen PF; Sen JW; Jørgensen TK; Hey A; Kragh M
    Clin Cancer Res; 2011 Sep; 17(18):5962-72. PubMed ID: 21825041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action.
    Ganter B; Tugendreich S; Pearson CI; Ayanoglu E; Baumhueter S; Bostian KA; Brady L; Browne LJ; Calvin JT; Day GJ; Breckenridge N; Dunlea S; Eynon BP; Furness LM; Ferng J; Fielden MR; Fujimoto SY; Gong L; Hu C; Idury R; Judo MS; Kolaja KL; Lee MD; McSorley C; Minor JM; Nair RV; Natsoulis G; Nguyen P; Nicholson SM; Pham H; Roter AH; Sun D; Tan S; Thode S; Tolley AM; Vladimirova A; Yang J; Zhou Z; Jarnagin K
    J Biotechnol; 2005 Sep; 119(3):219-44. PubMed ID: 16005536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.
    Lebrec H; Narayanan P; Nims R
    J Appl Toxicol; 2010 Jul; 30(5):387-96. PubMed ID: 20589744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extracting quantitative information from tissue--an industrial perspective.
    Van Osta P
    Cytometry A; 2006 Jul; 69(7):588-91. PubMed ID: 16680702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery.
    Fischer HP
    Biotechnol Annu Rev; 2005; 11():1-68. PubMed ID: 16216773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reality check for device-drug convergence.
    Ratner M
    Nat Biotechnol; 2007 Feb; 25(2):157-9. PubMed ID: 17287739
    [No Abstract]   [Full Text] [Related]  

  • 37. Russia through the prism of the world biopharmaceutical market.
    Bairamashvili DI; Rabinovich ML
    Biotechnol J; 2007 Jul; 2(7):801-17. PubMed ID: 17615600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human antibodies from transgenic animals.
    Lonberg N
    Nat Biotechnol; 2005 Sep; 23(9):1117-25. PubMed ID: 16151405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery.
    Sakagami M
    Adv Drug Deliv Rev; 2006 Oct; 58(9-10):1030-60. PubMed ID: 17010473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of systems approaches on biological problems in drug discovery.
    Hood L; Perlmutter RM
    Nat Biotechnol; 2004 Oct; 22(10):1215-7. PubMed ID: 15470453
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.